On November 18, 2026 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, reported that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) has been selected for oral presentation at the IASLC/ASCO 2026 North America Conference on Lung Cancer (NACLC26), taking place December 4–6, 2026. A trial in progress (TiP) abstract on the Phase 2 TARGET-D 202 registration-directed NSCLC trial has also been accepted for poster presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"For people with KRAS G12D-mutated lung cancer, the need for targeted treatment options remains significant. No therapy specifically targeting KRAS G12D is approved, and published research has associated this mutation with worse outcomes, including lower response rates and shorter progression-free survival than other common KRAS variants in metastatic NSCLC," said Michael G. Kauffman, M.D., Ph.D., President of Development at Verastem Oncology. "We’re advancing VS-7375, an investigational oral, selective KRAS G12D (ON/OFF) inhibitor with best-in-class potential to enable maximal antitumor efficacy with a favorable tolerability profile. The updated TARGET-D 101 data to be presented at the conference build on the findings we reported in October — including confirmed responses in previously treated NSCLC, with responses observed in patients who had received taxanes. Together, these findings support our broader strategy to move VS-7375 toward the frontline setting."
Late-Breaking Oral Presentation
Title: Preliminary Efficacy and Safety of VS-7375 in Previously Treated KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer: Results From the Phase 1/2 TARGET-D-101 Study
Date and time: Saturday, December 5, 2026, 2:45-4:15 p.m. MST
Presenter: Marcelo V. Negrao, M.D., Department of Thoracic-Head & Neck Med Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center
Abstract Session: Oral Abstract Session 1 (OA01)
TiP Poster Presentation
Title: TARGET-D 202: A Phase 2 Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer
Date and time: Saturday, December 5, 2026, 4:15-5:45 p.m. MST
Presenter: Matthew Gumbleton, M.D., Ph.D., Assistant Professor at the University of Utah, Huntsman Cancer Institute
Poster Session: Poster Viewing Reception (PP01.119)
About KRAS G12D
KRAS G12D represents 26% of all KRAS mutations, making it the most prevalent KRAS mutation in human cancers. When the KRAS gene is mutated, it can promote cancer development and growth. Patients with KRAS G12D-mutant tumors often have poorer outcomes, underscoring the need for therapies designed specifically to inhibit this mutation potently and for a long duration. The KRAS G12D mutation occurs most commonly in pancreatic (40%), colorectal (15%), and non-small cell lung (5%) cancers. Currently, no therapies are approved by the U.S. Food and Drug Administration (FDA) specifically targeting KRAS G12D mutations in cancer.
About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor & TARGET-D Clinical Program
VS-7375 is a potential best-in-class, potent, and selective investigational oral KRAS G12D dual ON/OFF inhibitor. It is designed to uniquely bind to both the active (ON) and inactive (OFF) states of KRAS G12D, with the potential to inhibit KRAS G12D signaling and tumor growth more completely than compounds that block KRAS G12D only in the OFF state or only in the ON state.
In June 2025, Verastem initiated TARGET-D 101, a Phase 1/2 dose escalation, dose expansion, and combination clinical trial evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors. Verastem has further expanded the VS-7375 clinical program with the initiation of three Phase 2 registration-directed, open-label clinical trials that are enrolling patients: TARGET-D 201 (NCT07644559) in metastatic pancreatic ductal carcinoma, TARGET-D 202 (NCT07659782) in advanced non-small cell lung cancer, and TARGET-D 203 (NCT07659795) in metastatic colorectal cancer.
In July 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to VS-7375 for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic pancreatic ductal carcinoma who have received at least one prior line of standard systemic therapy. In June 2026, the FDA also granted FTD to VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody either concurrently or sequentially.
In January 2025, Verastem exercised its license for VS-7375 from GenFleet Therapeutics. The license gives Verastem development and commercialization rights outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan. GenFleet is developing VS-7375 as GFH375 in China.
(Press release, Verastem, NOV 18, 2026, View Source [SID1234674921])